Stress-Induced Hyperglycaemia in Non-Diabetic Patients with Acute Coronary Syndrome: From Molecular Mechanisms to New Therapeutic Perspectives
Open accessThe DOI matches its Crossref record; 209 of the 216 references it cites were found in a registry or an index.
Abstract
Stress-induced hyperglycaemia (SIH) at hospital admission for acute coronary syndrome is associated with poor outcome, especially in patients without known diabetes. Nevertheless, insulin treatment in these subjects was not correlated with the reduction of mortality. This is likely due to the fact that SIH in the context of an acute coronary syndrome, compared to that in known diabetes, represents an epiphenomenon of other pathological conditions, such as adrenergic and renin-angiotensin system over-activity, hyperglucagonaemia, increase of circulating free fatty acids and pancreatic beta-cell dysfunction, which are not completely reversed by insulin therapy and so worsen the prognosis. Thus, SIH may be considered not only as a biomarker of organ damage, but also as an indicator of a more complex therapeutic strategy in these subjects. The aim of this review is to analyse the molecular mechanisms by which SIH may favour a worse prognosis in non-diabetic patients with acute coronary syndrome and identify new therapeutic strategies, in addition to insulin therapy, for a more appropriate treatment and improved outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stress hyperglycaemia without diabetes is associated with adverse in-hospital outcomes, and should be suspected in those with raised glucose levels during admission and normal HbA1c.19”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Collet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
Self-citationCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Julius, S., Kjeldsen, S. E., Weber, M., Brunner, H. R., Ekman, S., Hansson, L., Hua, T., Laragh, J., McInnes, G. T., Mitchell, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16451-9 · Cited by 2,558
Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J.-P., & Colette, C. (2006) · JAMA · doi:10.1001/jama.295.14.1681 · Cited by 2,444 · cited 1×
“Interestingly, data from human studies suggest that acute fluctuations in glucose levels may have an even more powerful impact on oxidative stress than chronic and sustained hyperglycaemia [66].”
BackgroundCapes, S. E., Hunt, D., Malmberg, K., & Gerstein, H. C. (2000) · The Lancet · doi:10.1016/s0140-6736(99)08415-9 · Cited by 2,187 · cited 1×
“suggested some explanations to justify the worse outcome of hyperglycaemic non-diabetic patients compared to hyperglycaemic diabetic patients [4].”
ResultMechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Esposito, K., Nappo, F., Marfella, R., Giugliano, G., Giugliano, F., Ciotola, M., Quagliaro, L., Ceriello, A., & Giugliano, D. (2002) · Circulation · doi:10.1161/01.cir.0000034509.14906.ae · Cited by 1,961 · cited 2×
“TNF-α has been shown to extend infarct size in experimental settings and to induce cardiac myocyte apoptosis [60,61].”
BackgroundSelf-citationHernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Dungan, K. M., Braithwaite, S. S., & Preiser, J.-C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60553-5 · Cited by 1,431
Ray, K. K., Seshasai, S. R. K., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., Erqou, S., & Sattar, N. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60697-8 · Cited by 1,383
Malmberg, K. (1997) · BMJ · doi:10.1136/bmj.314.7093.1512 · Cited by 1,286
Angiotensin-neprilysin inhibition in acute decompensated heart failure
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812851 · Cited by 1,260
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189
Role of Mitochondrial Dysfunction in Insulin Resistance
Kim, J.-A., Wei, Y., & Sowers, J. R. (2008) · Circulation Research · doi:10.1161/circresaha.107.165472 · Cited by 1,103
Malmberg, K., Rydén, L., Wedel, H., Birkeland, K., Bootsma, A., Dickstein, K., Efendic, S., Fisher, M., Hamsten, A., Herlitz, J., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi199 · Cited by 1,048
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis
Elliott, W. J., & Meyer, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60108-1 · Cited by 1,016
Hypoglycemia and risk of death in critically ill patients
The NICE-SUGAR Study Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204942 · Cited by 1,009
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901
Malmberg, K., Norhammar, A., Wedel, H., & Rydén, L. (1999) · Circulation · doi:10.1161/01.cir.99.20.2626 · Cited by 847
Bakris, G. L., Fonseca, V., Katholi, R. E., McGill, J. B., Messerli, F. H., Phillips, R. A., Raskin, P., Wright, J. T., Oakes, R., Lukas, M. A., et al. (2004) · JAMA · doi:10.1001/jama.292.18.2227 · Cited by 792
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Omland, T., Aakvaag, A., Bonarjee, V. V. S., Caidahl, K., Lie, R. T., Nilsen, D. W. T., Sundsfjord, J. A., & Dickstein, K. (1996) · Circulation · doi:10.1161/01.cir.93.11.1963 · Cited by 700
Kawano, H., Motoyama, T., Hirashima, O., Hirai, N., Miyao, Y., Sakamoto, T., Kugiyama, K., Ogawa, H., & Yasue, H. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00168-0 · Cited by 676 · cited 1×
“Human studies have also linked elevated glucose levels with endothelial dysfunction, as measured by endothelium-mediated brachial artery vasodilation, in which the level of endothelial dysfunction was correlated with the level of hyperglycaemia [52].”
BackgroundTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Kosiborod, M., Rathore, S. S., Inzucchi, S. E., Masoudi, F. A., Wang, Y., Havranek, E. P., & Krumholz, H. M. (2005) · Circulation · doi:10.1161/circulationaha.104.517839 · Cited by 666 · cited 1×
“found a tight relation between high glycaemic levels at hospital admission and 30-day/1-year mortality in over 140,000 patients with ACS [5].”
BackgroundFarilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664
The CREATE-ECLA Trial Group Investigators* (2005) · JAMA · doi:10.1001/jama.293.4.437 · Cited by 641
Vallon, V., & Thomson, S. C. (2017) · Diabetologia · doi:10.1007/s00125-016-4157-3 · Cited by 635
Glucose Challenge Stimulates Reactive Oxygen Species (ROS) Generation by Leucocytes
Mohanty, P. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2970 · Cited by 622 · cited 1×
“Another possible explanation of why hyperglycaemia is worsening the prognosis more in ACS people without diabetes than in those with diabetes is related to the evidence that acute hyperglycaemia promotes oxidative stress, which, in turn, can induce tissue injury [9,10] and may lead to bad CV outcomes [11,12].”
BackgroundCardiac Steatosis in Diabetes Mellitus: A 1 H-Magnetic Resonance Spectroscopy Study
McGavock, J. M., Lingvay, I., Zib, I., Tillery, T., Salas, N., Unger, R., Levine, B. D., Raskin, P., Victor, R. G., & Szczepaniak, L. S. (2007) · Circulation · doi:10.1161/circulationaha.106.645614 · Cited by 612 · cited 1×
“Excess circulating FFAs may also increase myocardial diastolic dysfunction [79].”
BackgroundNauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Verma, S., Mazer, C. D., Yan, A. T., Mason, T., Garg, V., Teoh, H., Zuo, F., Quan, A., Farkouh, M. E., Fitchett, D. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042375 · Cited by 572
Jacobi, J., Bircher, N., Krinsley, J., Agus, M., Braithwaite, S. S., Deutschman, C., Freire, A. X., Geehan, D., Kohl, B., Nasraway, S. A., et al. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e3182653269 · Cited by 571
Collet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4418 · Cited by 562
Self-citationExenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
Lønborg, J., Vejlstrup, N., Kelbæk, H., Bøtker, H. E., Kim, W. Y., Mathiasen, A. B., Jørgensen, E., Helqvist, S., Saunamäki, K., Clemmensen, P., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr309 · Cited by 550
Gillingham, L. G., Harris‐Janz, S., & Jones, P. J. H. (2011) · Lipids · doi:10.1007/s11745-010-3524-y · Cited by 546
Ramipril and the Development of Diabetes
Yusuf, S. (2001) · JAMA · doi:10.1001/jama.286.15.1882 · Cited by 541 · cited 1×
“Interventional studies have documented that angiotensin converting enzyme (ACE)inhibitors [39] and angiotensin receptor blockers (ARBs) [40] reduce the incidence of type 2 diabetes mellitus (T2DM).”
BackgroundMetabolic Modulation of Acute Myocardial Infarction: The ECLA Glucose-Insulin-Potassium Pilot Trial
Díaz, R., Paolasso, E. A., Piegas, L. S., Tajer, C. D., Moreno, M. G., Corvalán, R., Isea, J. E., Romero, G., & (Estudios Cardiológicos Latinoamérica) Collaborative Group (1998) · Circulation · doi:10.1161/01.cir.98.21.2227 · Cited by 517
Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias
Oliver, E. F., & Opie, L. H. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90939-3 · Cited by 508 · cited 1×
“The leading mechanisms to explain such effects are the membrane-damaging detergent properties of FFAs [77] and an increased oxygen demand due to mitochondrial uncoupling, which underlies the FFAs-induced increase in myocardial oxygen consumption and local heat production [78].”
BackgroundLee, T.-M., Chang, N.-C., & Lin, S.-Z. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.035 · Cited by 504
Sympathetic Overstimulation During Critical Illness: Adverse Effects of Adrenergic Stress
Dünser, M. W., & Hasibeder, W. R. (2009) · Journal of Intensive Care Medicine · doi:10.1177/0885066609340519 · Cited by 488 · cited 1×
“Under extreme stress conditions, such as after acute myocardial infarction (AMI) and cardiac arrest, epinephrine levels can markedly increase and may have a greater effect on glucagon secretion in the critically ill patient [30,31].”
Background10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487
Insulin resistance and hypertension
Sowers, J. R. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00026.2004 · Cited by 471
Timmers, L., Henriques, J. P. S., de Kleijn, D. P. V., DeVries, J. H., Kemperman, H., Steendijk, P., Verlaan, C. W. J., Kerver, M., Piek, J. J., Doevendans, P. A., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.033 · Cited by 470
Abuissa, H., Jones, P. G., Marso, S. P., & O’Keefe, J. H. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.051 · Cited by 452
Mu, J., Woods, J., Zhou, Y.-P., Roy, R. S., Li, Z., Zycband, E., Feng, Y., Zhu, L., Li, C., Howard, A. D., et al. (2006) · Diabetes · doi:10.2337/db05-1602 · Cited by 449
Gersh, B. J., Stone, G. W., White, H. D., & Holmes, D. R. (2005) · JAMA · doi:10.1001/jama.293.8.979 · Cited by 439
Morigi, M., Angioletti, S., Imberti, B., Donadelli, R., Micheletti, G., Figliuzzi, M., Remuzzi, A., Zoja, C., & Remuzzi, G. (1998) · Journal of Clinical Investigation · doi:10.1172/jci656 · Cited by 438 · cited 1×
“In vitro and in vivo studies also demonstrated induction of the proinflammatory transcription factor NF-κB in a setting of elevated glucose [62,63].”
BackgroundSuh, S. W., Gum, E. T., Hamby, A. M., Chan, P. H., & Swanson, R. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30077 · Cited by 419 · cited 1×
“but especially does during glucose reperfusion after hypoglycaemia [70].”
BackgroundIwakura, K., Ito, H., Ikushima, M., Kawano, S., Okamura, A., Asano, K., Kuroda, T., Tanaka, K., Masuyama, T., Hori, M., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02626-8 · Cited by 408 · cited 1×
“showed a higher incidence of the no-reflow phenomenon in patients with elevated glucose levels after successful reperfusion [50].”
BackgroundWahab, N. N., Cowden, E. A., Pearce, N. J., Gardner, M. J., Merry, H., & Cox, J. L. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02483-x · Cited by 393 · cited 1×
“SIH in the context of an acute coronary syndrome (ACS) is associated with a poor outcome in patients with or without known diabetes [2,3].”
BackgroundCollet, J.-P., & Thiele, H. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa624 · Cited by 386
Kosiborod, M. (2009) · JAMA · doi:10.1001/jama.2009.496 · Cited by 364
Insulin-Resistant Cardiomyopathy
Witteles, R. M., & Fowler, M. B. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.021 · Cited by 351 · cited 1×
“The elevated plasma FFAs are preferentially oxidized by skeletal and cardiac muscle, hence impairing the uptake and oxidation of glucose [36] and directly contributing to IR [37,38].”
BackgroundFitchett, D., Inzucchi, S. E., Cannon, C. P., McGuire, D. K., Scirica, B. M., Johansen, O. E., Sambevski, S., Kaspers, S., Pfarr, E., George, J. T., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037778 · Cited by 351
Vascular disease and diabetes: Is hypoglycaemia an aggravating factor?
Wright, R. J., & Frier, B. M. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.865 · Cited by 336 · cited 1×
“Further results suggest that hypoglycaemia may play an important role in the vascular damage [67].”
BackgroundThe Hyperglycemia: Intensive Insulin Infusion In Infarction (HI-5) Study
Cheung, N. W., Wong, V. W., & McLean, M. (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-1894 · Cited by 335 · cited 1×
“The HI-5 study was the first RCT of intensive insulin infusion that included hyperglycaemic ACS patients without previously established diabetes [85].”
BackgroundFurtado, R. H. M., Bonaca, M. P., Raz, I., Zelniker, T. A., Mosenzon, O., Cahn, A., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.039996 · Cited by 329
Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism.
Cockcroft, J. R., Chowienczyk, P. J., Brett, S. E., Chen, C. P., Dupont, A. G., Van Nueten, L., Wooding, S. J., & Ritter, J. M. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10549-1 · Cited by 324
Ceriello, A., Russo, P. D., Amstad, P., & Cerutti, P. (1996) · Diabetes · doi:10.2337/diab.45.4.471 · Cited by 324 · cited 1×
“Chronic hyperglycaemia induces antioxidant defences in cells and tissues [13,14].”
BackgroundSelf-citationNorhammar, A. M., Rydén, L., & Malmberg, K. (1999) · Diabetes Care · doi:10.2337/diacare.22.11.1827 · Cited by 315 · cited 1×
“SIH in the context of an acute coronary syndrome (ACS) is associated with a poor outcome in patients with or without known diabetes [2,3].”
BackgroundSvensson, A.-M., McGuire, D. K., Abrahamsson, P., & Dellborg, M. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi230 · Cited by 310
Guha, M., Bai, W., Nadler, J. L., & Natarajan, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.23.17728 · Cited by 309 · cited 1×
“Another possible explanation of why hyperglycaemia is worsening the prognosis more in ACS people without diabetes than in those with diabetes is related to the evidence that acute hyperglycaemia promotes oxidative stress, which, in turn, can induce tissue injury [9,10] and may lead to bad CV outcomes [11,12].”
BackgroundSattar, N., McLaren, J., Kristensen, S. L., Preiss, D., & McMurray, J. J. (2016) · Diabetologia · doi:10.1007/s00125-016-3956-x · Cited by 309
Glucagon and the a Cell: Physiology and Pathophysiology(First of Two Parts)
Unger, R. H., & Orci, L. (1981) · New England Journal of Medicine · doi:10.1056/nejm198106183042504 · Cited by 299
Zhao, T., Parikh, P., Bhashyam, S., Bolukoglu, H., Poornima, I., Shen, Y.-T., & Shannon, R. P. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.100982 · Cited by 297
SHAMOON, H., HENDLER, R., & SHERWIN, R. S. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-52-6-1235 · Cited by 295 · cited 1×
“Consistently, the sympathetic nervous system activation induced by ACS further stimulates glucagon release [19,20].”
BackgroundImproved Islet Morphology after Blockade of the Renin- Angiotensin System in the ZDF Rat
Tikellis, C., Wookey, P. J., Candido, R., Andrikopoulos, S., Thomas, M. C., & Cooper, M. E. (2004) · Diabetes · doi:10.2337/diabetes.53.4.989 · Cited by 286
Morohoshi, M., Fujisawa, K., Uchimuraa, I., & Numano, F. (1996) · Diabetes · doi:10.2337/diab.45.7.954 · Cited by 281
Acute Hyperglycemia Induces Nitrotyrosine Formation and Apoptosis in Perfused Heart From Rat
Ceriello, A., Quagliaro, L., D’Amico, M., Di Filippo, C., Marfella, R., Nappo, F., Berrino, L., Rossi, F., & Giugliano, D. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1076 · Cited by 279 · cited 1×
“Another possible explanation of why hyperglycaemia is worsening the prognosis more in ACS people without diabetes than in those with diabetes is related to the evidence that acute hyperglycaemia promotes oxidative stress, which, in turn, can induce tissue injury [9,10] and may lead to bad CV outcomes [11,12].”
BackgroundSelf-citationAngiotensin II–Induced Insulin Resistance Is Associated With Enhanced Insulin Signaling
Ogihara, T., Asano, T., Ando, K., Chiba, Y., Sakoda, H., Anai, M., Shojima, N., Ono, H., Onishi, Y., Fujishiro, M., et al. (2002) · Hypertension · doi:10.1161/01.hyp.0000040262.48405.a8 · Cited by 274 · cited 1×
“In addition, tempol restored insulin sensitivity in AT-II-infused rats, as well as enhanced insulin-induced PI3K activation, suggesting that the development of AT-II-induced IR can be antagonized by removing the oxidative stress [45].”
BackgroundProtein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction
Byon, J. C. H., Kusari, A. B., & Kusari, J. (1998) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006868409841 · Cited by 269 · cited 1×
“In particular, PTPase-1B seems to play a critical role in insulin action [42].”
Backgroundvan der Horst, I. C. C., Zijlstra, F., van't Hof, A. W. J., Doggen, C. J. M., de Boer, M.-J., Suryapranata, H., Hoorntje, J. C. A., Dambrink, J.-H. E., Gans, R. O. B., & Bilo, H. J. G. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00830-1 · Cited by 260 · cited 1×
“The GIPS-I study showed a clinical benefit of GIK therapy in STEMI patients without signs of HF [94].”
MethodWallhaus, T. R., Taylor, M., DeGrado, T. R., Russell, D. C., Stanko, P., Nickles, R. J., & Stone, C. K. (2001) · Circulation · doi:10.1161/01.cir.103.20.2441 · Cited by 253
Effects of Antihypertensive Therapy on Serum Lipids
Kasiske, B. L., Ma, J. Z., Kalil, R. S. N., & Louis, T. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-2-199501150-00010 · Cited by 252
Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle
Brehm, A., Krssak, M., Schmid, A. I., Nowotny, P., Waldhäusl, W., & Roden, M. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-1286 · Cited by 239 · cited 1×
“The elevated plasma FFAs are preferentially oxidized by skeletal and cardiac muscle, hence impairing the uptake and oxidation of glucose [36] and directly contributing to IR [37,38].”
BackgroundKlein, J., Fasshauer, M., Ito, M., Lowell, B. B., Benito, M., & Kahn, C. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34795 · Cited by 238 · cited 1×
“For instance, β3-AR stimulation in adipocytes impairs insulin signalling within few minutes [32], whereas, in cardiac myocytes, stimulation of β1-AR has a biphasic effect on insulin-stimulated glucose uptake, with an initial additive action, followed by an inhibitory one [33], due to an impairment of MAPK phosphatase-…”
BackgroundDiamant, M., Nauck, M. A., Shaginian, R., Malone, J. K., Cleall, S., Reaney, M., de Vries, D., Hoogwerf, B. J., MacConell, L., Wolffenbuttel, B. H. R., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0876 · Cited by 228
Catecholamines in myocardial ischemia. Systemic and cardiac release.
Schömig, A. (1990) · PubMed · Cited by 227
Woo, J. S., Kim, W., Ha, S. J., Kim, J. B., Kim, S.-J., Kim, W.-S., Seon, H. J., & Kim, K. S. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301586 · Cited by 223
McGuire, D. K., Van de Werf, F., Armstrong, P. W., Standl, E., Koglin, J., Green, J. B., Bethel, M. A., Cornel, J. H., Lopes, R. D., Halvorsen, S., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.0103 · Cited by 217
Beshansky, J. R. (2012) · JAMA · doi:10.1001/jama.2012.426 · Cited by 216 · cited 1×
“Finally, the IMMEDIATE study showed that, among patients with suspected ACS, out-of-hospital administration of intravenous GIK, compared with glucose placebo, did not reduce progression to myocardial infarction [98].”
MethodGillespie, E. L., White, C. M., Kardas, M., Lindberg, M., & Coleman, C. I. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2261 · Cited by 215
NFkappaB is a Key Player in the Crosstalk between Inflammation and Cardiovascular Diseases
Fiordelisi, A., Iaccarino, G., Morisco, C., Coscioni, E., & Sorriento, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071599 · Cited by 215 · cited 1×
“This inflammatory response evokes a detrimental effect on injured myocardium [64].”
BackgroundSelf-citationLongchain n−3 polyunsaturated fatty acids and blood vessel function
Abeywardena, M. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00406-0 · Cited by 214
Husain, M., Bain, S. C., Jeppesen, O. K., Lingvay, I., Sørrig, R., Treppendahl, M. B., & Vilsbøll, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13955 · Cited by 209
Andreozzi, F., Laratta, E., Sciacqua, A., Perticone, F., & Sesti, G. (2004) · Circulation Research · doi:10.1161/01.res.0000126501.34994.96 · Cited by 208 · cited 1×
“This event impairs the interaction of IRS-1 with the p85 regulatory subunit of PI3K and compromises the insulin-mediated vasodilatory effect [46].”
BackgroundINITIAL METABOLIC AND HORMONAL RESPONSE TO ACUTE MYOCARDIAL INFARCTION
Vetter, N. J., Adams, W., Strange, R. C., & Oliver, M. F. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92595-1 · Cited by 207 · cited 1×
“Moreover, the initial pain-related burst of catecholamine release: (1) mobilizes free fatty acids (FFAs) from adipose tissue; (2) acutely inhibits the release of insulin from the pancreas; and (3) causes hyperglycaemia [35].”
BackgroundCeriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S. (2013) · Diabetes Care · doi:10.2337/dc12-2469 · Cited by 204
Self-citationBanarer, S., McGregor, V. P., & Cryer, P. E. (2002) · Diabetes · doi:10.2337/diabetes.51.4.958 · Cited by 194 · cited 1×
“There is evidence that most of the inhibitory effect of insulin on glucagon secretion is mediated by paracrine effects within the pancreatic islets [25].”
BackgroundHyperglycemia-Induced Thrombin Formation in Diabetes: The Possible Role of Oxidative Stress
Ceriello, A., Giacomello, R., Stel, G., Motz, E., Taboga, C., Tonutti, L., Pirisi, M., Falleti, E., & Bartoli, E. (1995) · Diabetes · doi:10.2337/diab.44.8.924 · Cited by 193
Self-citationAcute hyperglycemia abolishes ischemic preconditioning in vivo
Kersten, J. R., Schmeling, T. J., Orth, K. G., Pagel, P. S., & Warltier, D. C. (1998) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1998.275.2.h721 · Cited by 192 · cited 1×
“showed an impairment of collateral circulation associated with increased infarct size in the setting of severe hyperglycaemia [47,48].”
BackgroundGlycemic Variability and Mortality in Critically 111 Patients: The Impact of Diabetes
Krinsley, J. S. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300609 · Cited by 192
Celik, T., Iyisoy, A., Kursaklioglu, H., Kardesoglu, E., Kilic, S., Turhan, H., Yilmaz, M. I., Ozcan, O., Yaman, H., Isik, E., et al. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000209993.26057.de · Cited by 189
Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism
Nyström, T., Gonon, A. T., Sjöholm, Å., & Pernow, J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.024 · Cited by 188
Goyal, A., Mahaffey, K. W., Garg, J., Nicolau, J. C., Hochman, J. S., Weaver, W. D., Theroux, P., Oliveira, G. B. F., Todaro, T. G., Mojcik, C. F., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi884 · Cited by 184
Lahnwong, C., Palee, S., Apaijai, N., Sriwichaiin, S., Kerdphoo, S., Jaiwongkam, T., Chattipakorn, S. C., & Chattipakorn, N. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01066-9 · Cited by 181
Glucose-Insulin-Potassium Therapy in Patients With ST-Segment Elevation Myocardial Infarction
Díaz, R., Goyal, A., Mehta, S. R., Afzal, R., Xavier, D., Pais, P., Chrolavicius, S., Zhu, J., Kazmi, K., Liu, L., et al. (2007) · JAMA · doi:10.1001/jama.298.20.2399 · Cited by 175
Ishibashi, Y., Matsui, T., Takeuchi, M., & Yamagishi, S.-I. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.075 · Cited by 173
Glucagon and the a Cell: Physiology and Pathophysiology
Unger, R. H., & Orci, L. (1981) · New England Journal of Medicine · doi:10.1056/nejm198106253042604 · Cited by 170
Aljada, A., Ghanim, H., Mohanty, P., Syed, T., Bandyopadhyay, A., & Dandona, P. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.1.51 · Cited by 167 · cited 1×
“Moreover, glucose ingestion in healthy human volunteers is associated with increased production of other proinflammatory factors, such as activator protein 1 and early growth response 1, and increased expression of the genes regulated by them, including the genes for matrix metalloproteinases-2 and -9 and tissue facto…”
BackgroundMarx, N., & McGuire, D. K. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw110 · Cited by 165
Lenzen, M., Ryden, L., Ohrvik, J., Bartnik, M., Malmberg, K., Scholte op Reimer, W., Simoons, M. L., & on behalf of the Euro Heart Survey Investigators (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl363 · Cited by 164 · cited 1×
“Finally, they remarked that a patient with known diabetes is more likely to receive insulin therapy, although almost two-thirds of the patients hospitalised for ACS with hyperglycaemia at admission showed impaired glucose tolerance (IGT) or a newly diagnosed diabetes at three months after discharge [7,8].”
BackgroundSingh, P. K., Jain, A., & Kaur, G. (2004) · Molecular and Cellular Biochemistry · doi:10.1023/b:mcbi.0000026067.08356.13 · Cited by 163 · cited 1×
“During hypoglycaemia, oxidative stress is produced at the mitochondrial level [68], similarly to in hyperglycaemia [69].”
BackgroundAljada, A., Friedman, J., Ghanim, H., Mohanty, P., Hofmeyer, D., Chaudhuri, A., & Dandona, P. (2006) · Metabolism · doi:10.1016/j.metabol.2006.04.016 · Cited by 158
Andraws, R., & Brown, D. L. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.10.068 · Cited by 158
Verma, S., McMurray, J. J. V., & Cherney, D. Z. I. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.1891 · Cited by 158
Gupta, D. K., Jewitt, D. E., Young, R., Hartog, M., & Opie, L. H. (1969) · The Lancet · doi:10.1016/s0140-6736(69)90749-1 · Cited by 157 · cited 2×
“Such FFA levels are reached in the early hours of ACS [75,76].”
BackgroundResultCeriello, A., Novials, A., Ortega, E., La Sala, L., Pujadas, G., Testa, R., Bonfigli, A. R., Esposito, K., & Giugliano, D. (2012) · Diabetes · doi:10.2337/db12-0224 · Cited by 155 · cited 2×
“In particular, GLP-1 has anti-inflammatory and antiatherogenic properties [148,189–193], and it counterbalances oxidative stress induced by both hyperglycaemia and hypoglycaemia in T1DM [194].”
BackgroundSelf-citationTimmer, J. R., Ottervanger, J. P., de Boer, M., Dambrink, J. E., Hoorntje, J. C. A., Gosselink, A. T. M., Suryapranata, H., Zijlstra, F., & Hof, A. W. J. V. ’. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.12.050 · Cited by 150 · cited 1×
“Moreover, hyperglycaemic patients with STEMI have lower rates of spontaneous reperfusion [49].”
BackgroundInsulin Reciprocally Regulates Glucagon Secretion in Humans
Cooperberg, B. A., & Cryer, P. E. (2010) · Diabetes · doi:10.2337/db10-0728 · Cited by 147 · cited 1×
“Because of beta-cells dysfunction, insulin may be absent or low in ACS when a patient is often not eating normal amounts of food and when stress levels of catecholamines, which suppress insulin secretion, are very high [23,24].”
BackgroundAcute hyperglycaemia: a ‘new’ risk factor during myocardial infarction
Ceriello, A. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi049 · Cited by 145 · cited 1×
“Another possible explanation of why hyperglycaemia is worsening the prognosis more in ACS people without diabetes than in those with diabetes is related to the evidence that acute hyperglycaemia promotes oxidative stress, which, in turn, can induce tissue injury [9,10] and may lead to bad CV outcomes [11,12].”
BackgroundSelf-citationPandolfi, A., Giaccari, A., Cilli, C., Alberta, M. M., Morviducci, L., De Filippis, E. A., Buongiorno, A., Pellegrini, G., Capani, G., & Consoli, A. (2001) · Acta Diabetologica · doi:10.1007/s005920170016 · Cited by 144 · cited 1×
“Acutely, hyperglycaemia in rats evokes the decrease of tissue plasminogen activator activity and increases plasminogen activator inhibitor levels [53].”
BackgroundMarfella, R., Filippo, C. D., Portoghese, M., Ferraraccio, F., Rizzo, M. R., Siniscalchi, M., Musacchio, E., D’Amico, M., Rossi, F., & Paolisso, G. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.041 · Cited by 142 · cited 1×
“In particular, some of these demonstrated a positive effect of tight glycaemic control, associated to the achievement of glucose target, compared to standard therapy on myocardial injury in hyperglycaemic patients addressed to coronary artery bypass graft (CABG) [87,88] or pPCI [89,90].”
ResultGlucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control
Anagnostis, P., Athyros, V. G., Adamidou, F., Panagiotou, A., Kita, M., Karagiannis, A., & Mikhailidis, D. P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01345.x · Cited by 141
Akt Mediates the Cross-Talk Between β-Adrenergic and Insulin Receptors in Neonatal Cardiomyocytes
Morisco, C., Condorelli, G., Trimarco, V., Bellis, A., Marrone, C., Condorelli, G., Sadoshima, J., & Trimarco, B. (2005) · Circulation Research · doi:10.1161/01.res.0000152968.71868.c3 · Cited by 141 · cited 1×
“For instance, β3-AR stimulation in adipocytes impairs insulin signalling within few minutes [32], whereas, in cardiac myocytes, stimulation of β1-AR has a biphasic effect on insulin-stimulated glucose uptake, with an initial additive action, followed by an inhibitory one [33], due to an impairment of MAPK phosphatase-…”
BackgroundSelf-citationThe Role of the New β-Blockers in Treating Cardiovascular Disease
Weber, M. A. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.09.009 · Cited by 136
Messerli, F. H., Bangalore, S., & Julius, S. (2008) · Circulation · doi:10.1161/circulationaha.107.695007 · Cited by 132
Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury
Tanajak, P., Sa‐nguanmoo, P., Sivasinprasasn, S., Thummasorn, S., Siri‐Angkul, N., Chattipakorn, S. C., & Chattipakorn, N. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0457 · Cited by 131
Tansey, M. J. B., & Opie, L. H. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90388-4 · Cited by 127 · cited 1×
“Finally, higher glucose levels exert a detrimental effect during ACS because they are also associated with higher FFAs concentrations leading to a direct myocardial injury [72,73].”
BackgroundVerma, S., Poulter, N. R., Bhatt, D. L., Bain, S. C., Buse, J. B., Leiter, L. A., Nauck, M. A., Pratley, R. E., Zinman, B., Ørsted, D. D., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034516 · Cited by 127
Honigberg, M. C., Chang, L.-S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1966 · Cited by 127
Brixius, K., Bundkirchen, A., Bölck, B., Mehlhorn, U., & Schwinger, R. H. G. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704188 · Cited by 125
Chen, W. R., Hu, S. Y., Chen, Y. D., Zhang, Y., Qian, G., Wang, J., Yang, J. J., Wang, Z. F., Tian, F., & Ning, Q. X. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.07.014 · Cited by 123
Plasma Catecholamines and Carbohydrate Metabolism in Patients with Acute Myocardial Infarction
Christensen, N. J., & Videbaek, J. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107763 · Cited by 121 · cited 1×
“Consistently, the sympathetic nervous system activation induced by ACS further stimulates glucagon release [19,20].”
BackgroundRitsinger, V., Malmberg, K., Mårtensson, A., Rydén, L., Wedel, H., & Norhammar, A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70088-9 · Cited by 118
Marso, S. P., Baeres, F. M. M., Bain, S. C., Goldman, B., Husain, M., Nauck, M. A., Poulter, N. R., Pratley, R. E., Thomsen, A. B., & Buse, J. B. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.063 · Cited by 118
Free radicals, cytokines and nitric oxide in cardiac failure and myocardial infarction
Das, U. N. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1026579422132 · Cited by 113 · cited 1×
“TNF-α has been shown to extend infarct size in experimental settings and to induce cardiac myocyte apoptosis [60,61].”
BackgroundTaniyama, Y., Hitomi, H., Shah, A., Alexander, R. W., & Griendling, K. K. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000164313.17167.df · Cited by 113
Bartnik, M., Malmberg, K., Hamsten, A., Efendic, S., Norhammar, A., Silveira, A., Tenerz, Å., Öhrvik, J., & Rydén, L. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01371.x · Cited by 112 · cited 3×
“Conversely, the pro-insulin levels were significantly increased in patients compared to control subjects indicating impaired beta-cell function among these subjects [7,16].”
BackgroundWan, J.-B., Huang, L.-L., Rong, R., Tan, R., Wang, J., & Kang, J. X. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.210054 · Cited by 109
Mason, R. P., Kubant, R., Jacob, R. F., Walter, M. F., Boychuk, B., & Maliñski, T. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000238593.67191.e2 · Cited by 108
Sinnaeve, P. R. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.572 · Cited by 108
Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients
Poirier, L., Cléroux, J., Nadeau, A., & Lacourcière, Y. (2001) · Journal of Hypertension · doi:10.1097/00004872-200108000-00011 · Cited by 108
Chen, W. R., Chen, Y. D., Tian, F., Yang, N., Cheng, L. Q., Hu, S. Y., Wang, J., Yang, J. J., Wang, S. F., & Gu, X. F. (2016) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.116.005146 · Cited by 100
Fudim, M., White, J., Pagidipati, N. J., Lokhnygina, Y., Wainstein, J., Murin, J., Iqbal, N., Öhman, P., Lopes, R. D., Reicher, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041659 · Cited by 99
Taborsky, G. J. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400607 · Cited by 96
Hyperglycemia reduces coronary collateral blood flow through a nitric oxide-mediated mechanism
Kersten, J. R., Toller, W. G., Tessmer, J. P., Pagel, P. S., & Warltier, D. C. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.281.5.h2097 · Cited by 95 · cited 1×
“showed an impairment of collateral circulation associated with increased infarct size in the setting of severe hyperglycaemia [47,48].”
BackgroundLi, D., Zhao, L., Liu, M., Du, X., Ding, W., Zhang, J., & Mehta, J. L. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70375-3 · Cited by 93
Blood glucose may condition factor VII levels in diabetic and normal subjects
Ceriello, A., Giugliano, D., Quatraro, A., Russo, P. D., & Torella, R. (1988) · Diabetologia · doi:10.1007/bf00265372 · Cited by 91
Self-citationEffect of inhibition of lipolysis on myocardial oxygen consumption in the presence of isoproterenol
Mjøs, O. D. (1971) · Journal of Clinical Investigation · doi:10.1172/jci106679 · Cited by 91
Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes
Oliver, M. F. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01104-4 · Cited by 91 · cited 1×
“Finally, higher glucose levels exert a detrimental effect during ACS because they are also associated with higher FFAs concentrations leading to a direct myocardial injury [72,73].”
BackgroundHuthmacher, J. A., Meier, J. J., & Nauck, M. A. (2020) · Diabetes Care · doi:10.2337/dc20-0498 · Cited by 91
Inhibition of Glucagon Secretion
Young, A. (2005) · Advances in pharmacology · doi:10.1016/s1054-3589(05)52008-8 · Cited by 90 · cited 1×
“Because of beta-cells dysfunction, insulin may be absent or low in ACS when a patient is often not eating normal amounts of food and when stress levels of catecholamines, which suppress insulin secretion, are very high [23,24].”
BackgroundChen, W.-R., Shen, X., Zhang, Y., Chen, Y., Hu, S.-Y., Qian, G., Wang, J., Yang, J., Wang, Z., & Tian, F. (2015) · Endocrine · doi:10.1007/s12020-015-0798-0 · Cited by 89
Effects of free fatty acid and enzyme release in experimental glucose on myocardial infarction
de Leiris, J., Opie, L. H., & Lubbe, W. F. (1975) · Nature · doi:10.1038/253746a0 · Cited by 86 · cited 2×
“When circulating FFAs are high enough to exceed the tight binding sites on the albumin, they determine an increased enzyme release in the ischemic myocardium [74].”
BackgroundRenal antioxidant enzyme mRNA levels are increased in rats with experimental diabetes mellitus
Sechi, L. A., Ceriello, A., Griffin, C. A., Catena, C., Amstad, P., Schambelan, M., & Bartoli, E. (1997) · Diabetologia · doi:10.1007/s001250050638 · Cited by 85 · cited 1×
“Chronic hyperglycaemia induces antioxidant defences in cells and tissues [13,14].”
BackgroundSelf-citationClinical experience with glucose-insulin-potassium therapy in acute myocardial infarction
Rackley, C. E., Russell, R. O., Rogers, W. J., Mantle, J. A., McDaniel, H. G., & Papapietro, S. E. (1981) · American Heart Journal · doi:10.1016/0002-8703(81)90488-9 · Cited by 82
Marfella, R., Sasso, F. C., Siniscalchi, M., Paolisso, P., Rizzo, M. R., Ferraro, F., Stabile, E., Sorropago, G., Calabrò, P., Carbonara, O., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1364 · Cited by 81 · cited 1×
“In particular, some of these demonstrated a positive effect of tight glycaemic control, associated to the achievement of glucose target, compared to standard therapy on myocardial injury in hyperglycaemic patients addressed to coronary artery bypass graft (CABG) [87,88] or pPCI [89,90].”
ResultSelf-citationWallander, M., Bartnik, M., Efendić, S., Hamsten, A., Malmberg, K., Öhrvik, J., Rydén, L., Silveira, A. M. V., & Norhammar, A. (2005) · Diabetologia · doi:10.1007/s00125-005-1931-z · Cited by 78 · cited 2×
“Conversely, the pro-insulin levels were significantly increased in patients compared to control subjects indicating impaired beta-cell function among these subjects [7,16].”
BackgroundPlasma Interleukin-10 Levels and Adverse Outcomes in Acute Coronary Syndrome
Çavuşoğlu, E., Marmur, J. D., Hojjati, M. R., Chopra, V., Butala, M., Subnani, R., Huda, M. S., Yanamadala, S., Ruwende, C., Eng, C., et al. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.02.040 · Cited by 77
Tripolt, N. J., Kolesnik, E., Pferschy, P. N., Verheyen, N., Ablasser, K., Sailer, S., Alber, H. F., Berger, R., Kaulfersch, C., Leitner, K., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.12.004 · Cited by 73
Dietary monounsaturated fatty acids appear not to provide cardioprotection.
Degirolamo, C., & Rudel, L. L. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0133-4 · Cited by 72
Sardu, C., Barbieri, M., Balestrieri, M. L., Siniscalchi, M., Paolisso, P., Calabrò, P., Minicucci, F., Signoriello, G., Portoghese, M., Mone, P., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0795-8 · Cited by 71 · cited 1×
“Consistently, thrombus aspiration during primary percutaneous intervention (pPCI) for STEMI reduced clinical outcomes in hyperglycaemic patients, whereas it did not in normoglycaemic ones [51].”
BackgroundSelf-citationGlycaemic control in acute coronary syndromes: prognostic value and therapeutic options
De Caterina, R., Madonna, R., Sourij, H., & Wascher, T. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq162 · Cited by 69
Tight Glycemic Control May Increase Regenerative Potential of Myocardium during Acute Infarction
Marfella, R., Sasso, F. C., Cacciapuoti, F., Portoghese, M., Rizzo, M. R., Siniscalchi, M., Carbonara, O., Ferraraccio, F., Torella, M., Petrella, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2037 · Cited by 69 · cited 1×
“In particular, some of these demonstrated a positive effect of tight glycaemic control, associated to the achievement of glucose target, compared to standard therapy on myocardial injury in hyperglycaemic patients addressed to coronary artery bypass graft (CABG) [87,88] or pPCI [89,90].”
ResultKojima, T., Hikoso, S., Nakatani, D., Suna, S., Dohi, T., Mizuno, H., Okada, K., Kitamura, T., Kida, H., Oeun, B., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.12.034 · Cited by 69 · cited 1×
“However, it has been recently reported that in ST-elevation myocardial infarction (STEMI) patients discharged alive, SIH is significantly associated with worse long-term prognosis in the non-diabetic population [15].”
BackgroundMarfella, R., Rizzo, M. R., Siniscalchi, M., Paolisso, P., Barbieri, M., Sardu, C., Antonella, S., Angelico, N., Gaudio, S. D., Esposito, N., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.06.053 · Cited by 68 · cited 1×
“In particular, some of these demonstrated a positive effect of tight glycaemic control, associated to the achievement of glucose target, compared to standard therapy on myocardial injury in hyperglycaemic patients addressed to coronary artery bypass graft (CABG) [87,88] or pPCI [89,90].”
ResultSelf-citationWillerson, J. T., Hutcheson, D. R., Leshin, S. J., Faloona, G. R., & Unger, R. H. (1974) · The American Journal of Medicine · doi:10.1016/0002-9343(74)90848-1 · Cited by 68 · cited 1×
“In particular, it is well known that pancreatic beta-cell dysfunction affects insulin release [7,16], thereby increasing glucagon and glucose levels in acute ill conditions, such as ACS [17,18].”
BackgroundInsulin Resistance and Cardiovascular Risk: New Insights From Molecular and Cellular Biology
Morisco, C., Lembo, G., & Trimarco, B. (2006) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2006.03.008 · Cited by 65 · cited 1×
“In this regard, it has been documented that, in vascular smooth muscle cells isolated from rat thoracic aorta, AT-II profoundly decreases IRS-1 protein levels via ROS-mediated phosphorylation of IRS-1 on Ser307 and subsequent proteasome-dependent degradation [43,44].”
BackgroundSelf-citationTimmer, J. R., Svilaas, T., Ottervanger, J. P., Henriques, J. P. S., Dambrink, J. E., van den Broek, S. A. J., van der Horst, I. C. C., & Zijlstra, F. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.01.040 · Cited by 65 · cited 1×
“On the contrary, the GIPS-II trial, designed to confirm the positive results of GIPS-I in STEMI patients receiving reperfusion therapy, did not show any trend toward a therapeutic benefit [95].”
ResultAngiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance
Henriksen, E. J., & Jacob, S. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00265.x · Cited by 63
Lamping, K. G., Nuno, D. W., Coppey, L. J., Holmes, A. J., Hu, S., Oltman, C. L., Norris, A. W., & Yorek, M. A. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12004 · Cited by 60
McCormick, L. M., Kydd, A. C., Read, P. A., Ring, L. S., Bond, S. J., Hoole, S. P., & Dutka, D. P. (2014) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.113.000785 · Cited by 59
Vergès, B. L., Avignon, A., Bonnet, F., Catargi, B., Cattan, S., Cosson, E., Ducrocq, G., Elbaz, M., Fredenrich, A., Gourdy, P., et al. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.11.003 · Cited by 55
Nomoto, H., Miyoshi, H., Sugawara, H., Ono, K., Yanagiya, S., Oita, M., Nakamura, A., & Atsumi, T. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0255-8 · Cited by 46
de Mulder, M., Umans, V. A., Cornel, J. H., van der Zant, F. M., Stam, F., Oemrawsingh, R. M., Akkerhuis, K. M., & Boersma, E. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.10074 · Cited by 45 · cited 1×
“Conversely, others did not evidence a significant statistical difference in achieved target glycaemic values, as well as in 90-day mortality or extension of myocardial injury between two therapeutic strategies [91,92].”
BackgroundMORISCO, C., MARRONE, C., TRIMARCO, V, CRISPO, S., MONTI, M., SADOSHIMA, J., & TRIMARCO, B. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.07.012 · Cited by 45 · cited 1×
“For instance, β3-AR stimulation in adipocytes impairs insulin signalling within few minutes [32], whereas, in cardiac myocytes, stimulation of β1-AR has a biphasic effect on insulin-stimulated glucose uptake, with an initial additive action, followed by an inhibitory one [33], due to an impairment of MAPK phosphatase-…”
BackgroundSelf-citationKahles, F., Rückbeil, M. V., Mertens, R. W., Foldenauer, A. C., Arrivas, M. C., Moellmann, J., Lebherz, C., Biener, M., Giannitsis, E., Katus, H. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz728 · Cited by 44
Matsumura, M., Nakatani, Y., Tanka, S., Aoki, C., Sagara, M., Yanagi, K., Suzuki, K., & Aso, Y. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0274-3 · Cited by 41
Hyperglycemia may determine fibrinopeptide A plasma level increase in humans
Ceriello, A., Giugliano, D., Quatraro, A., Russo, P. D., Marchi, E., & Torella, R. (1989) · Metabolism · doi:10.1016/0026-0495(89)90152-2 · Cited by 38
Self-citationInsulin Resistance Predicts Severity of Coronary Atherosclerotic Disease in Non-Diabetic Patients
Strisciuglio, T., Izzo, R., Barbato, E., Gioia, G. D., Colaiori, I., Fiordelisi, A., Morisco, C., Bartúnek, J., Franco, D., Ammirati, G., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072144 · Cited by 37
Self-citationIncreased Local Metabolic Rate by Free Fatty Acids in the Intact Dog Heart
Mjøs, O. D., & KJEKSHUS, J. K. (1971) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365517109095714 · Cited by 36
Effect of antilipolytic therapy on ST segment elevation during myocardial ischaemia in man.
Russell, D. C., & Oliver, M. F. (1978) · Heart · doi:10.1136/hrt.40.2.117 · Cited by 32
Effect of Hyperglycemia and Insulin in Acute Coronary Syndromes
Dandona, P., Chaudhuri, A., Ghanim, H., & Mohanty, P. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.04.004 · Cited by 31
Lee, S., Min, K. W., Lee, B., Jeong, I., Yoo, S.-J., Kwon, H., Choi, Y., & Yoon, K. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0203 · Cited by 30
Han, S. J., Choi, S., KANG, Y. Y., Jung, J. G., Yi, S., Kim, H. J., Lee, K. W., & Kim, D. J. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.01.016 · Cited by 28
Diebold, S., Moellmann, J., Kahles, F., Haj‐Yehia, E., Liehn, E. A., Nickel, A. G., Lebherz, C., Maack, C., Marx, N., & Lehrke, M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13472 · Cited by 28
Baseline glucose and left ventricular remodeling after acute myocardial infarction
Nicolau, J. C., Maia, L. N., Vitola, J. V., Mahaffey, K. W., Machado, M. D. N., & Ramires, J. A. F. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2006.01.003 · Cited by 24
Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure
Verbrugge, F. H. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0340-1 · Cited by 23
Hage, C., Brismar, K., Efendic, S., Lundman, P., Rydén, L., & Mellbin, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12032 · Cited by 22
Gigante, B., Bellis, A., Visconti, R., Marino, M., Morisco, C., Trimarco, V., Galasso, G., Piscione, F., LUCA, N. D., Prince, J. A., et al. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.140541 · Cited by 22 · cited 1×
“In addition, it is also reasonable to hypothesize that the detrimental effects of SIH in ACS can be amplified by the genetic variants of the coagulation factors resulting in a vicious circle that amplify the platelet aggregation and the prothrombotic state [57].”
BackgroundSelf-citationIgarashi, N., Nozawa, T., Fujii, N., Suzuki, T., Matsuki, A., Nakadate, T., Igawa, A., & Inoue, H. (2006) · Circulation Journal · doi:10.1253/circj.70.1509 · Cited by 21
Buono, F., Spinelli, L., Giallauria, F., di Panzillo, E. A., Marino, S. D., Ferrara, F., Vigorito, C., Trimarco, B., & Morisco, C. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.01.066 · Cited by 19 · cited 1×
“These data allow to hypothesize that the tight control of glycaemia prevents the post-infarction left ventricular remodelling (LVR), which still affects the 30% of ACS patients [86].”
BackgroundSelf-citationIncretin treatment and atherosclerotic plaque stability: Role of adiponectin/APPL1 signaling pathway
Barbieri, M., Marfella, R., Esposito, A., Rizzo, M. R., Angellotti, E., Mauro, C., Siniscalchi, M., Chirico, F., Caiazzo, P., Furbatto, F., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.001 · Cited by 19
Self-citationNeuroendocrine activation after acute myocardial infarction
Cohn, J. N. (1990) · The American Journal of Cardiology · doi:10.1016/0002-9149(90)90122-h · Cited by 18
Research works printed but not linked: 1
- Diaz, 1998, Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group, Circulation, 98, 2227
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Caturano, A., Galiero, R., Pafundi, P. C., Cesaro, A., Vetrano, E., Palmiero, G., Rinaldi, L., Salvatore, T., Marfella, R., Sardu, C., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108959 · Cited by 73
Cui, K., Fu, R., Yang, J., Xu, H., Yin, D., Song, W., Wang, H., Zhu, C., Feng, L., Wang, Z., et al. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3562 · Cited by 68
“In addition, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporters two inhibitors may significantly reduce the glucose levels and ischaemic cardiovascular events.(34,36)”
BackgroundLi, X., Yang, X., Dong, B.-B., & Liu, Q. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02577-z · Cited by 63
Lin, Z., Liang, X., Zhang, Y., Dai, Y., Zeng, L., Chen, W., Kong, S., He, P., Duan, C., & Liu, Y. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01799-3 · Cited by 56
Metadata
- Authors
- Bellis, A., Mauro, C., Barbato, E., Ceriello, A., Cittadini, A., & Morisco, C.
- Affiliations
- Ospedale Antonio Cardarelli (IT)
- University of Naples Federico II (IT)
- MultiMedica (IT)
- Corresponding author
- Morisco, Carmine
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-01-14
- Volume
- 22
- Issue
- 2
- Pages
- 775
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7828822
- OpenAlex
- W3121056265
- Cited by
- 61
- References
- 216
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 14 · 2023: 10 · 2022: 7 · 2021: 4
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- stress hyperglycemia, acute coronary syndrome, non-diabetic patients, insulin therapy, prognosis, adrenergic system, renin-angiotensin system, hyperglucagonaemia, free fatty acids, beta-cell dysfunction, molecular mechanisms, treatment options
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Adrenergic beta-Antagonists, Angiotensin-Converting Enzyme Inhibitors, Animals, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin, Stress, Psychological, Acute Coronary Syndrome, Dipeptidyl-Peptidase IV Inhibitors, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.